Evobrutinib

Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases[1].

Product Specifications

CAS Number

[1415823-73-2]

Product Name Alternative

M2951; MSC2364447C

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Btk

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Evobrutinib.html

Purity

99.60

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

C=CC(N1CCC(CNC2=NC=NC(N)=C2C3=CC=C(OC4=CC=CC=C4)C=C3)CC1)=O

Molecular Formula

C25H27N5O2

Molecular Weight

429.51

Precautions

H315, H319, H335

References & Citations

[1]Caldwell R, et al. Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Aug 1.